[Clinical usefulness of combination treatment with thiazolidinedione and insulin].
Because most type-2 Diabetes Mellitus(DM) is a consequence of both impaired insulin secretion and insulin resistance, it should be treated most efficiently using insulin and thiazolidinedione(TZD), a novel insulin-sensitizer, in combination. In our study, patients with non-obese type-2 DM treated with insulin alone were further administered with TZD. In 80% of patients, addition of TZD caused not only the decrease in insulin dosage and/or HbA1c but also the decrease in hypoglycemic events presumably through improvement in insulin profile, i.e. endogenous:exogenous ratio. More importantly, TZD did not cause unfavorable increase in BMI and patients positively accepted these changes. We conclude that combination of TZD and insulin is a good regimen for non-obese type-2 DM.
Kitamura
R
R
Third Department of Internal Medicine, National Defense Medical College.
Tanaka
Y
Y
D002839:Chromans / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D007328:Insulin / Q000008:administration & dosage*; D015337:Multicenter Studies as Topic; D000077205:Pioglitazone; D013844:Thiazoles / Q000008:administration & dosage* / Q000009:adverse effects; D045162:Thiazolidinediones; D000077288:Troglitazone
D002839:Chromans; D007004:Hypoglycemic Agents; D007328:Insulin; D013844:Thiazoles; D045162:Thiazolidinediones; C089946:2,4-thiazolidinedione; D000077288:Troglitazone; D000077205:Pioglitazone